SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001347178-18-000010
Filing Date
2018-11-07
Accepted
2018-11-07 17:08:34
Documents
81
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda0930201810q.htm 10-Q 993868
2 EX-10.41 vndaex104109302018.htm EX-10.41 53491
3 EX-31.1 vndaex31109302018.htm EX-31.1 13566
4 EX-31.2 vndaex31209302018.htm EX-31.2 13534
5 EX-32.1 vndaex32109302018.htm EX-32.1 9467
  Complete submission text file 0001347178-18-000010.txt   5688250

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT vnda-20180930.xml EX-101.INS 1066988
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20180930.xsd EX-101.SCH 55455
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20180930_cal.xml EX-101.CAL 94333
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20180930_def.xml EX-101.DEF 221622
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20180930_lab.xml EX-101.LAB 629331
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20180930_pre.xml EX-101.PRE 382256
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 181167281
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1